Biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday that it is set to present key findings from its solid tumour pipeline at the European Society for Medical Oncology (ESMO) Congress 2024, including data on mirvetuximab soravtansine (ELAHERE) and c-Met targeting antibody-drug conjugates (ADCs) Teliso-V and ABBV-400. The company's ADCs are designed to target biomarkers such as folate receptor-alpha (FRα) and c-Met, associated with poor prognosis in various cancers.

Data from the Phase 2 PICCOLO trial of mirvetuximab soravtansine showed a 51.9% objective response rate in heavily pre-treated patients with FRα-positive platinum-sensitive ovarian cancer (PSOC), with a median duration of response of 8.3 months. The safety profile was consistent with previous studies, with no new concerns reported.

Exploratory patient-reported outcomes from the Phase 2 LUMINOSITY trial of Teliso-V, a c-Met targeting ADC, in advanced non-small cell lung cancer (NSCLC) will also be presented. Additionally, new safety and efficacy data for ABBV-400, a next-generation c-Met ADC, demonstrated antitumor activity in pre-treated NSCLC and gastroesophageal cancer patients.

AbbVie's robust oncology portfolio continues to evolve with a focus on addressing high unmet needs in solid tumours, advancing targeted therapies across multiple cancer types.